Big Data's double-edged sword: Better drug marketing, bigger SG&A cost cuts
12.03.2014 / Fierce Pharma
Big Data could be a big deal for Big Pharma's commercial operations. It could help top drugmakers slash another $35 billion-plus in costs over the next several years, to keep margins up. But it's small drugmakers that could benefit most strategically, a new report finds.